Lysosomal acid lipase and PPAR gamma ligands as immune therapies for cancer treatment
US10857209B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 2017 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | Jul 3, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of cancer treatment are disclosed. Particularly, disclosed herein are methods of administering LAL and PPARγ ligands for treating various cancer patients to promote anti-cancer immunity (suppress MDSC), use for inhibiting tumor progression, and use for inhibiting tumor metastasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.